US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
US20050089958A1
(en)
*
|
1996-01-09 |
2005-04-28 |
Genentech, Inc. |
Apo-2 ligand
|
US6998116B1
(en)
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
EP0904366A1
(en)
|
1996-04-01 |
1999-03-31 |
Genentech, Inc. |
Apo-2li and apo-3 apoptosis polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US6462176B1
(en)
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
US5990281A
(en)
*
|
1996-09-30 |
1999-11-23 |
Genentech, Inc. |
Vertebrate smoothened proteins
|
US6136958A
(en)
*
|
1996-09-30 |
2000-10-24 |
Genentech, Inc. |
Antibodies to vertebrate smoothened proteins
|
ATE356212T1
(en)
|
1997-01-31 |
2007-03-15 |
Genentech Inc |
O-FUKOSYL TRANSFERASE
|
CA2289665C
(en)
|
1997-06-13 |
2005-08-09 |
Genentech, Inc. |
Protein recovery by chromatography followed by filtration upon a charged layer
|
PT1015587E
(en)
|
1997-09-18 |
2008-07-31 |
Genentech Inc |
Dcr3 polypeptide, a tnfr homolog
|
EP1967587A1
(en)
|
1997-10-10 |
2008-09-10 |
Genentech, Inc. |
APO-3 Ligand
|
IL135607A0
(en)
|
1997-10-29 |
2001-05-20 |
Genentech Inc |
Wnt-1 inducible genes
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
CA2309358A1
(en)
|
1997-11-21 |
1999-06-03 |
Genentech, Inc. |
A-33 related antigens and their pharmacological uses
|
NZ527898A
(en)
|
1997-12-03 |
2005-01-28 |
Genentech Inc |
PRO347 polypeptides and nucleic acids encoding proteins with homology to cysteine-rich secretory protein-3
|
EP1947119A3
(en)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
|
CA2318029C
(en)
|
1998-01-15 |
2009-05-19 |
Genentech, Inc. |
Apo-2 ligand
|
DE69936382T3
(en)
|
1998-05-15 |
2011-07-07 |
Genentech, Inc., Calif. |
THERAPEUTIC USES OF IL-17 HOMOLOGOUS POLYPEPTIDE
|
EP1950300A3
(en)
|
1998-11-18 |
2011-03-23 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
EP1820859B9
(en)
|
1998-12-22 |
2009-10-28 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
AU778759B2
(en)
|
1998-12-23 |
2004-12-16 |
Genentech Inc. |
IL-1 related polypeptides
|
NZ539776A
(en)
|
1999-01-15 |
2006-12-22 |
Genentech Inc |
Polypeptide variants with altered effector function
|
AU5152700A
(en)
|
1999-06-15 |
2001-01-02 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
IL146954A0
(en)
|
1999-06-25 |
2002-08-14 |
Genentech Inc |
HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
|
KR20090126330A
(en)
|
1999-08-27 |
2009-12-08 |
제넨테크, 인크. |
Dosages for treatment with anti-erbb2 antibodies
|
EP1690872A3
(en)
|
1999-12-01 |
2006-08-23 |
Genentech, Inc. |
Composition and methods for the diagnosis of tumours
|
EP2290081A3
(en)
|
1999-12-23 |
2012-08-01 |
Genentech, Inc. |
IL-17 homologous polypeptide and therapeutic uses thereof
|
CN1425066B
(en)
|
2000-01-13 |
2010-05-26 |
杰南技术公司 |
Novel stra6 polypeptides
|
US6740520B2
(en)
|
2000-03-21 |
2004-05-25 |
Genentech, Inc. |
Cytokine receptor and nucleic acids encoding the same
|
EP2792747A1
(en)
|
2000-06-23 |
2014-10-22 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
EP2075253A1
(en)
|
2000-06-23 |
2009-07-01 |
Genentech, Inc. |
Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
|
DE60136816D1
(en)
|
2000-07-27 |
2009-01-15 |
Genentech Inc |
SEQUENTIAL ADMINISTRATION OF CPT-11 AND APO-2L POLYPEPTIDE
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(en)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
|
ATE412009T1
(en)
|
2000-08-24 |
2008-11-15 |
Genentech Inc |
METHOD FOR INHIBITING IL-22 INDUCED PAP1
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
AU2002213441B2
(en)
|
2000-10-12 |
2006-10-26 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
CA2448956C
(en)
|
2001-05-30 |
2017-10-03 |
Genentech, Inc. |
Anti-ngf antibodies for the treatment of various disorders
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
ATE522623T1
(en)
|
2001-06-20 |
2011-09-15 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG TUMORS
|
KR101008785B1
(en)
|
2001-08-29 |
2011-01-14 |
제넨테크, 인크. |
Bv8 Nucleic Acids and Polypeptides with Mitogenic Activity
|
EP2153843B1
(en)
|
2001-09-18 |
2012-08-15 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2005049075A2
(en)
|
2003-11-17 |
2005-06-02 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
WO2004039826A1
(en)
|
2001-11-14 |
2004-05-13 |
Centocor, Inc. |
Anti-il-6 antibodies, compositions, methods and uses
|
EP1464702A4
(en)
|
2001-12-28 |
2005-09-21 |
Chugai Pharmaceutical Co Ltd |
Method of stabilizing protein
|
JP2005525095A
(en)
|
2002-01-02 |
2005-08-25 |
ジェネンテック・インコーポレーテッド |
Compositions and methods for tumor diagnosis and treatment
|
US7452675B2
(en)
|
2002-01-25 |
2008-11-18 |
The Queen's Medical Center |
Methods of screening for TRPM4b modulators
|
WO2003072035A2
(en)
|
2002-02-22 |
2003-09-04 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US7303896B2
(en)
|
2002-02-25 |
2007-12-04 |
Genentech, Inc. |
Nucleic acid encoding novel type-1 cytokine receptor GLM-R
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
EP1585966B8
(en)
|
2002-07-15 |
2012-03-07 |
F. Hoffmann-La Roche AG |
Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4
|
DK2332996T3
(en)
|
2002-09-11 |
2014-12-15 |
Genentech Inc |
Purification of anti-Her2 antibodies
|
EP1578373A4
(en)
|
2002-09-11 |
2007-10-24 |
Genentech Inc |
Novel compositions and methods for the treatment of immune related diseases
|
EP2444409A2
(en)
|
2002-09-16 |
2012-04-25 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
AU2003279084A1
(en)
|
2002-09-25 |
2004-04-19 |
Genentech, Inc. |
Novel compositions and methods for the treatment of psoriasis
|
EP2322203A3
(en)
|
2002-10-29 |
2011-07-27 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
JP2006516094A
(en)
|
2002-11-08 |
2006-06-22 |
ジェネンテック・インコーポレーテッド |
Compositions and methods for treatment of natural killer cell related diseases
|
EP2314676A1
(en)
|
2002-11-26 |
2011-04-27 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
DK2270048T3
(en)
|
2002-12-24 |
2016-01-18 |
Rinat Neuroscience Corp |
Anti-NGF antibodies and methods for their use
|
EP1615659B1
(en)
|
2003-03-12 |
2014-04-16 |
Genentech, Inc. |
Use of bv8 and/or eg-vegf to promote hematopoiesis
|
AU2003237792A1
(en)
|
2003-04-01 |
2004-11-23 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CN1829741A
(en)
|
2003-05-30 |
2006-09-06 |
健泰科生物技术公司 |
Treatment with anti-VEGF antibodies
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
US20050095243A1
(en)
|
2003-06-05 |
2005-05-05 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
DE602004026724D1
(en)
|
2003-06-13 |
2010-06-02 |
Univ Pittsburgh |
MONITORING IMMUNOLOGICAL, HEMATOLOGIC AND INFLAMMATORY DISEASES
|
SI1641822T1
(en)
|
2003-07-08 |
2013-08-30 |
Genentech, Inc. |
Il-17 a/f heterologous polypeptides and therapeutic uses thereof
|
US7485704B2
(en)
|
2003-07-28 |
2009-02-03 |
Genentech, Inc. |
Reducing protein A leaching during protein A affinity chromatography
|
ATE528397T1
(en)
|
2003-08-08 |
2011-10-15 |
Perseus Proteomics Inc |
GENE OVEREXPRESSED IN CANCER
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
CN1914226B
(en)
|
2003-11-25 |
2012-02-01 |
达纳-法伯癌症研究院有限公司 |
Antibodies against SARS-COV and methods of use thereof
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
CA2548282A1
(en)
|
2003-12-11 |
2005-06-30 |
Genentech, Inc. |
Methods and compositions for inhibiting c-met dimerization and activation
|
JP4503617B2
(en)
|
2003-12-23 |
2010-07-14 |
ライナット ニューロサイエンス コーポレイション |
Agonist anti-trkC antibody and method using the antibody
|
ATE452147T1
(en)
|
2004-02-19 |
2010-01-15 |
Genentech Inc |
ANTIBODIES WITH CORRECTED CDR
|
BRPI0510915A
(en)
|
2004-06-04 |
2007-11-13 |
Genentech Inc |
Method for treating multiple sclerosis and manufactured article
|
DE602005019167D1
(en)
|
2004-07-20 |
2010-03-18 |
Genentech Inc |
ANGIOPOIETIN-LIKE 4 PROTEIN HEMMER COMBINATIONS AND THEIR USE
|
KR20070040824A
(en)
|
2004-07-30 |
2007-04-17 |
리나트 뉴로사이언스 코퍼레이션 |
Antibodies directed against amyloid-beta peptide and methods using same
|
JO3000B1
(en)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
Antibody Formulations.
|
EP1841793B1
(en)
|
2005-01-07 |
2010-03-31 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
EP1846030B1
(en)
|
2005-01-21 |
2018-11-21 |
Genentech, Inc. |
Fixed dosing of her antibodies
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
JP5651285B2
(en)
|
2005-02-15 |
2015-01-07 |
デューク ユニバーシティ |
Anti-CD19 antibodies and use in oncology
|
NZ590431A
(en)
|
2005-02-23 |
2012-08-31 |
Genentech Inc |
Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
|
CA2604621C
(en)
|
2005-04-11 |
2014-01-21 |
National Research Council Of Canada |
Identification of a beta-1,3-n-acetylgalactosaminyltransferase (cgte) from campylobacter jejuni lio87
|
DE602006018458D1
(en)
|
2005-04-29 |
2011-01-05 |
Univ California |
ANTIBODIES TO HISTONE MODIFICATIONS FOR CLINICAL CANCER DIAGNOSIS AND PROGNOSIS
|
PA8672101A1
(en)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
|
EP2221316A1
(en)
|
2005-05-05 |
2010-08-25 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
US8124084B2
(en)
|
2005-05-17 |
2012-02-28 |
University Of Connecticut |
Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
|
US7491391B2
(en)
|
2005-06-30 |
2009-02-17 |
Centocor, Inc. |
Anti-IL-23 antibodies, compositions, methods and uses
|
CA2618681C
(en)
|
2005-08-10 |
2015-10-27 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
KR20080068062A
(en)
|
2005-11-14 |
2008-07-22 |
리나트 뉴로사이언스 코퍼레이션 |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
WO2007126439A2
(en)
|
2005-12-02 |
2007-11-08 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
US8466263B2
(en)
|
2005-12-02 |
2013-06-18 |
Dana-Farber Cancer Institute, Inc. |
Carbonic anhydrase IX (G250) anitbodies
|
CN103396485B
(en)
|
2005-12-15 |
2016-08-10 |
健泰科生物技术公司 |
The method and composition of targeting polyubiquitin
|
CA2635692C
(en)
|
2005-12-29 |
2013-06-18 |
Centocor, Inc. |
Human anti-il-23 antibodies, compositions, methods and uses
|
WO2007130697A2
(en)
|
2006-01-05 |
2007-11-15 |
Genentech, Inc. |
Anti-ephb4 antibodies and methods using same
|
ATE491948T1
(en)
|
2006-02-06 |
2011-01-15 |
Rhode Island Hospital |
GPR30 ESTROGEN RECEPTOR IN MAMMARY CANCER
|
ZA200807714B
(en)
|
2006-02-17 |
2010-01-27 |
Genentech Inc |
Gene disruptions, compositions and methods relating thereto
|
WO2007103469A2
(en)
|
2006-03-06 |
2007-09-13 |
Aeres Biomedical Ltd. |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US20090130108A1
(en)
|
2006-03-21 |
2009-05-21 |
The Regents Of The University Of California |
N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy
|
US20100278821A1
(en)
|
2006-03-21 |
2010-11-04 |
The Regents Of The University Of California |
N-cadherin: target for cancer diagnosis and therapy
|
UA100969C2
(en)
|
2006-03-21 |
2013-02-25 |
Дженентек, Інк. |
Combinatorial therapy involving alpha5beta1 antagonists
|
EP2389946A1
(en)
|
2006-03-23 |
2011-11-30 |
Novartis AG |
Anti-tumor cell antigen antibody therapeutics
|
CA2647277A1
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
CN101479295A
(en)
|
2006-05-04 |
2009-07-08 |
健泰科生物技术公司 |
Methods and compositions relating to ZPA polypeptides
|
SG172656A1
(en)
|
2006-05-30 |
2011-07-28 |
Genentech Inc |
Antibodies and immunoconjugates and uses therefor
|
AU2007297869A1
(en)
|
2006-06-01 |
2008-03-27 |
Genentech, Inc. |
Crystal structure of CRig and C3b: CRig complex
|
ES2718952T3
(en)
|
2006-06-07 |
2019-07-05 |
Bioalliance Cv |
Antibodies that recognize an epitope that contains carbohydrates on CD-43 and CEA expressed in cancer cells and methods that use them
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
EP2037737B1
(en)
|
2006-07-11 |
2014-04-02 |
University Of Medicine And Dentistry Of New Jersey |
Cell membrane repair proteins, nucleic acids encoding the same and associated methods of use
|
DK2046809T3
(en)
|
2006-07-19 |
2017-03-13 |
Univ Pennsylvania |
WSX-1 / IL-27 AS A TARGET OBJECTIVE FOR ANTI-INFLAMMATORY REACTIONS
|
EP2057465A4
(en)
|
2006-08-09 |
2010-04-21 |
Homestead Clinical Corp |
Organ-specific proteins and methods of their use
|
CN104059149B
(en)
|
2006-08-22 |
2017-04-12 |
诺沃诺蒂斯克股份有限公司 |
Anti-C5aR antibodies with improved properties
|
JP2010501172A
(en)
|
2006-08-25 |
2010-01-21 |
オンコセラピー・サイエンス株式会社 |
Prognostic markers and therapeutic targets for lung cancer
|
CN101557818A
(en)
|
2006-10-03 |
2009-10-14 |
新泽西医科和牙科大学 |
ATAP peptides, nucleic acids encoding the same and associated methods of use
|
MX2009003938A
(en)
|
2006-10-27 |
2009-04-24 |
Genentech Inc |
Antibodies and immunoconjugates and uses therefor.
|
US8715653B2
(en)
|
2006-11-21 |
2014-05-06 |
The Regents Of The University Of California |
Modulation of Rhamm (CD168) for selective adipose tissue development
|
JP5391073B2
(en)
|
2006-11-27 |
2014-01-15 |
ディアデクサス インコーポレーテッド |
Ovr110 antibody compositions and methods of use
|
KR101508397B1
(en)
|
2007-02-22 |
2015-04-08 |
제넨테크, 인크. |
Methods for detecting inflammatory bowel disease
|
PE20090681A1
(en)
|
2007-03-02 |
2009-06-10 |
Genentech Inc |
PREDICTION OF RESPONSE TO A HER INHIBITOR
|
EP2703011A3
(en)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
JP2010526868A
(en)
|
2007-05-14 |
2010-08-05 |
ノビミューン エスアー |
Fc receptor binding polypeptide having altered effector function
|
CA2689302C
(en)
|
2007-06-08 |
2015-08-25 |
Australian Poultry Crc Pty Ltd. |
Clostridial toxin netb
|
US20100298156A1
(en)
|
2007-06-08 |
2010-11-25 |
Si Tuen Lee-Hoeflich |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
CN112480255A
(en)
|
2007-07-09 |
2021-03-12 |
健泰科生物技术公司 |
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
NZ602024A
(en)
|
2007-07-16 |
2014-04-30 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
JP2010533495A
(en)
|
2007-07-16 |
2010-10-28 |
ジェネンテック, インコーポレイテッド |
Humanized CD79b antibodies and immunoconjugates and their use
|
CA2695237A1
(en)
|
2007-08-02 |
2009-04-30 |
Novimmune S.A. |
Anti-rantes antibodies and methods of use thereof
|
ES2502217T3
(en)
|
2007-10-02 |
2014-10-03 |
Genentech, Inc. |
NLRR-1 antagonists and their uses
|
RU2503460C2
(en)
|
2007-11-07 |
2014-01-10 |
Дженентек Инк. |
Using antimicrobial polypeptide for treating microbial disorders
|
CN101970689A
(en)
|
2007-11-29 |
2011-02-09 |
健泰科生物技术公司 |
Gene expression markers for inflammatory bowel disease
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
AR069501A1
(en)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR)
|
BRPI0819714A8
(en)
|
2007-11-30 |
2016-05-10 |
Abbott Lab |
PROTEIN FORMULATIONS AND PRODUCTION METHODS THEREOF
|
MX2010006148A
(en)
|
2007-12-06 |
2011-02-23 |
Dana Farber Cancer Inst Inc |
Antibodies against influenza virus and methods of use thereof.
|
RU2570559C2
(en)
|
2007-12-17 |
2015-12-10 |
Пфайзер Лимитед |
Treatment of interstitial cystitis
|
CA2706502C
(en)
|
2007-12-18 |
2018-08-07 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
PT3043181T
(en)
|
2008-01-15 |
2020-06-17 |
Univ Leland Stanford Junior |
Markers of acute myeloid leukemia stem cells
|
TWI472339B
(en)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
|
NZ587132A
(en)
|
2008-01-31 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
MX364200B
(en)
|
2008-04-09 |
2019-04-16 |
Genentech Inc |
Novel compositions and methods for the treatment of immune related diseases.
|
SI2279004T1
(en)
|
2008-05-16 |
2015-05-29 |
F. Hoffmann-La Roche Ag |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
|
WO2009147781A1
(en)
|
2008-06-02 |
2009-12-10 |
国立大学法人東京大学 |
Antitumor agent
|
WO2009151514A1
(en)
|
2008-06-11 |
2009-12-17 |
Millipore Corporation |
Stirred tank bioreactor
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
EP3301116A1
(en)
|
2008-08-25 |
2018-04-04 |
Dana Farber Cancer Institute, Inc. |
Conserved influenza hemagglutinin epitope and antibodies thereto
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
BRPI0913476A2
(en)
|
2008-09-10 |
2015-12-01 |
Genentech Inc |
"Uses of a tspan12 antagonist and Uses of a norrin antagonist"
|
TWI445716B
(en)
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Pcsk9 antagonists
|
TW201438738A
(en)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
AU2009294415B2
(en)
|
2008-09-19 |
2015-09-24 |
Medimmune Llc |
Antibodies directed to DLL4 and uses thereof
|
TWI572357B
(en)
|
2008-10-14 |
2017-03-01 |
建南德克公司 |
Immunoglobulin variants and uses thereof
|
CN102438652B
(en)
|
2008-11-12 |
2014-08-13 |
米迪缪尼有限公司 |
Antibody formulation
|
JP2012512244A
(en)
|
2008-12-16 |
2012-05-31 |
イー・エム・デイー・ミリポア・コーポレイシヨン |
Protein purification
|
WO2010080528A1
(en)
|
2008-12-17 |
2010-07-15 |
Genentech, Inc. |
Hepatitis c virus combination therapy
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
JP6039183B2
(en)
|
2008-12-23 |
2016-12-07 |
ジェネンテック, インコーポレイテッド |
Immunoglobulin variants with altered binding to protein A
|
EP2379595A2
(en)
|
2008-12-23 |
2011-10-26 |
AstraZeneca AB |
Targeted binding agents directed to 5 1 and uses thereof
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
SI3260136T1
(en)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv) -neutralizing antibodies
|
CN102378767B
(en)
|
2009-03-25 |
2015-01-14 |
健泰科生物技术公司 |
Anti-fgfr3 antibodies and methods using same
|
EP2414399A1
(en)
|
2009-04-01 |
2012-02-08 |
F. Hoffmann-La Roche AG |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
SG175276A1
(en)
|
2009-05-05 |
2011-11-28 |
Novimmune Sa |
Anti-il-17f antibodies and methods of use thereof
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
KR20120051002A
(en)
|
2009-07-07 |
2012-05-21 |
제넨테크, 인크. |
Diagnosis and treatment of autoimmune demyelinating diseases
|
JP2012533322A
(en)
|
2009-07-20 |
2012-12-27 |
ジェネンテック, インコーポレイテッド |
Gene expression markers for Crohn's disease
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
KR20190018041A
(en)
|
2009-08-06 |
2019-02-20 |
제넨테크, 인크. |
Method to improve virus removal in protein purification
|
WO2011019620A1
(en)
|
2009-08-10 |
2011-02-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
WO2011019679A1
(en)
|
2009-08-11 |
2011-02-17 |
Allergan, Inc. |
Ccr2 inhibitors for treating conditions of the eye
|
PT2464725T
(en)
|
2009-08-11 |
2020-05-21 |
Hoffmann La Roche |
Production of proteins in glutamine-free cell culture media
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
WO2011028753A1
(en)
|
2009-09-01 |
2011-03-10 |
Genentech, Inc. |
Enhanced protein purification through a modified protein a elution
|
ES2599076T3
(en)
|
2009-09-02 |
2017-01-31 |
Genentech, Inc. |
Smoothened mutant and methods of use thereof
|
PL2486141T3
(en)
|
2009-10-07 |
2018-07-31 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
SG10201406420XA
(en)
|
2009-10-14 |
2014-11-27 |
Univ Nanyang Tech |
Antiproliferative agent
|
CA2778442A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
TW201121566A
(en)
|
2009-10-22 |
2011-07-01 |
Genentech Inc |
Anti-hepsin antibodies and methods using same
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
JP6173690B2
(en)
|
2009-11-05 |
2017-08-02 |
ジェネンテック, インコーポレイテッド |
Methods and compositions for secretion of heterologous polypeptides
|
JP2013510871A
(en)
|
2009-11-12 |
2013-03-28 |
ジェネンテック, インコーポレイテッド |
How to increase the density of dendritic spines
|
JP5911805B2
(en)
|
2009-11-20 |
2016-04-27 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Epithelial membrane protein-2 (EMP2) and proliferative vitreoretinopathy (PVR)
|
PT2504364T
(en)
|
2009-11-24 |
2017-11-14 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
MX2012006072A
(en)
|
2009-11-30 |
2012-07-23 |
Genentech Inc |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 ).
|
JP5818805B2
(en)
|
2009-12-11 |
2015-11-18 |
ジェネンテック, インコーポレイテッド |
Anti-VEGF-C antibody and method of use thereof
|
SG181834A1
(en)
|
2009-12-21 |
2012-07-30 |
Genentech Inc |
Antibody formulation
|
WO2011079185A1
(en)
|
2009-12-23 |
2011-06-30 |
Genentech, Inc. |
Anti-bv8 antibodies and uses thereof
|
JP5728718B2
(en)
|
2009-12-28 |
2015-06-03 |
オンコセラピー・サイエンス株式会社 |
Anti-CDH3 antibody and use thereof
|
US20110159588A1
(en)
|
2009-12-30 |
2011-06-30 |
Kui Lin |
Methods for Modulating a PDGF-AA Mediated Biological Response
|
US20130137584A1
(en)
|
2010-02-01 |
2013-05-30 |
The Regents Of The University Of California |
Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
|
CA2789629A1
(en)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc. |
Cd20 antibodies and uses thereof
|
EP4219560A3
(en)
|
2010-02-18 |
2023-08-23 |
The Regents of The University of California |
Integrin alpha v beta 8 neutralizing antibody
|
BR112012020373A8
(en)
|
2010-02-23 |
2018-01-02 |
Genentech Inc |
isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tat419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent
|
SA114360064B1
(en)
|
2010-02-24 |
2016-01-05 |
رينات نيوروساينس كوربوريشن |
Antagonist anti-il-7 receptor antibodies and methods
|
AU2011225716A1
(en)
|
2010-03-11 |
2012-09-27 |
Pfizer Inc. |
Antibodies with pH dependent antigen binding
|
CN103097416B
(en)
|
2010-03-30 |
2015-09-09 |
詹森生物科技公司 |
Humanization IL-25 antibody
|
EP2566510A1
(en)
|
2010-05-03 |
2013-03-13 |
F. Hoffmann-La Roche AG |
Compositions and methods useful for reducing the viscosity of protein-containing formulations
|
CN102958941A
(en)
|
2010-05-03 |
2013-03-06 |
霍夫曼-拉罗奇有限公司 |
Compositions and methods for the diagnosis and treatment of tumor
|
KR101827855B1
(en)
|
2010-05-17 |
2018-02-12 |
이엠디 밀리포어 코포레이션 |
Stimulus responsive polymers for the purification of biomolecules
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
NZ603648A
(en)
|
2010-05-25 |
2014-12-24 |
Genentech Inc |
Methods of purifying polypeptides
|
ES2599412T3
(en)
|
2010-05-28 |
2017-02-01 |
F. Hoffmann-La Roche Ag |
Decrease in the level of lactate and increase in the production of polypeptides by regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
|
WO2011153380A2
(en)
|
2010-06-02 |
2011-12-08 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
EP2577310B1
(en)
|
2010-06-03 |
2018-11-14 |
F.Hoffmann-La Roche Ag |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
NZ603581A
(en)
|
2010-06-19 |
2015-05-29 |
Sloan Kettering Inst Cancer |
Anti-gd2 antibodies
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
KR20130100125A
(en)
|
2010-08-13 |
2013-09-09 |
제넨테크, 인크. |
Antibodies to il-1beta and il-18, for treatment of disease
|
AU2011293127B2
(en)
|
2010-08-27 |
2016-05-12 |
Abbvie Stemcentrx Llc |
Notum protein modulators and methods of use
|
CA2809837C
(en)
|
2010-08-31 |
2019-12-31 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
SG10201506959SA
(en)
|
2010-09-03 |
2015-10-29 |
Stemcentrx Inc |
Novel modulators and methods of use
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
WO2012047968A2
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2012058768A1
(en)
|
2010-11-05 |
2012-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
EP2640831A1
(en)
|
2010-11-17 |
2013-09-25 |
Sea Lane Biotechnologies,llc. |
Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
RU2592672C9
(en)
|
2010-12-08 |
2016-11-27 |
СтемСентРкс, Инк. |
Novel modulators and methods for use thereof
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
SA112330278B1
(en)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
Novel modulators and methods of use
|
AU2012229188A1
(en)
|
2011-03-15 |
2013-09-26 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
CA2831732C
(en)
|
2011-03-31 |
2019-12-31 |
Genentech, Inc. |
Use of a monoclonal anti-beta7 antibody for treating gastrointestinal inflammatory disorders
|
CN103619881B
(en)
|
2011-04-07 |
2017-07-28 |
安姆根有限公司 |
New EGFR associated proteins
|
DK2714738T3
(en)
|
2011-05-24 |
2019-01-28 |
Zyngenia Inc |
MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
|
EP2734546A1
(en)
|
2011-07-18 |
2014-05-28 |
Amgen Inc. |
Apelin antigen-binding proteins and uses thereof
|
SI2773438T2
(en)
|
2011-11-02 |
2022-05-31 |
F.Hoffmann-La Roche Ag |
Overload and elute chromatography
|
CN109897103A
(en)
|
2011-11-04 |
2019-06-18 |
酵活有限公司 |
There is the antibody design of the stabilization heterodimeric of mutation in Fc structural domain
|
JP5936702B2
(en)
|
2011-11-11 |
2016-06-22 |
ライナット ニューロサイエンス コーポレイション |
Antibodies specific for TROP-2 and uses thereof
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
EP2794659A1
(en)
|
2011-12-22 |
2014-10-29 |
Rinat Neuroscience Corp. |
Human growth hormone receptor antagonist antibodies and methods of use thereof
|
US20130195851A1
(en)
|
2011-12-23 |
2013-08-01 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
CA2862979A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
WO2013106485A2
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
MY169341A
(en)
|
2012-02-06 |
2019-03-21 |
Inhibrx Inc |
Cd47 antibodies and methods of use thereof
|
PL2817338T3
(en)
|
2012-02-24 |
2017-12-29 |
Abbvie Stemcentrx Llc |
Dll3 modulators and methods of use
|
PL2831117T3
(en)
|
2012-03-29 |
2018-03-30 |
Novimmune Sa |
Anti-tlr4 antibodies and uses thereof
|
US9441045B2
(en)
|
2012-05-04 |
2016-09-13 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
|
EP2847230B1
(en)
|
2012-05-10 |
2020-08-12 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
EA201492282A1
(en)
|
2012-06-11 |
2015-07-30 |
Амген Инк. |
ANTAGONISTIC ANTIGENS-BINDING PROTEINS TO TWO RECEPTORS AND THEIR APPLICATION
|
WO2014018554A1
(en)
|
2012-07-23 |
2014-01-30 |
La Jolla Institute For Allergy And Immunology |
Ptprs and proteoglycans in autoimmune disease
|
KR20150076172A
(en)
|
2012-09-25 |
2015-07-06 |
그렌마크 파머수티칼스 에스. 아. |
Purification of Hetero-dimeric Immunoglobulins
|
WO2014055897A2
(en)
|
2012-10-04 |
2014-04-10 |
Dana-Farber Cancer Institute, Inc. |
Human monoclonal anti-pd-l1 antibodies and methods of use
|
PL2903691T3
(en)
|
2012-10-05 |
2019-10-31 |
Hoffmann La Roche |
Methods for diagnosing and treating inflammatory bowel disease
|
RU2015115956A
(en)
|
2012-11-09 |
2017-01-10 |
Пфайзер Инк. |
ANTIBODIES SPECIFIC TO THE THROMBOCYTE B GROWTH FACTOR, AND THEIR COMPOSITION AND APPLICATION
|
DK2925782T3
(en)
|
2012-12-03 |
2020-04-06 |
Novimmune Sa |
ANTI-CD47 ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
WO2014123580A1
(en)
|
2013-02-06 |
2014-08-14 |
Inhibrx Llc |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
RU2019109456A
(en)
|
2013-02-22 |
2019-04-10 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
NEW ANTIBODY CONJUGATES AND THEIR APPLICATIONS
|
KR102238379B1
(en)
|
2013-03-13 |
2021-04-09 |
제넨테크, 인크. |
Formulations with reduced oxidation
|
RS57813B1
(en)
|
2013-03-13 |
2018-12-31 |
Hoffmann La Roche |
Formulations with reduced oxidation
|
RU2019120404A
(en)
|
2013-03-13 |
2019-08-06 |
Дженентек, Инк. |
COMPOSITIONS OF ANTIBODIES
|
WO2014144061A2
(en)
|
2013-03-15 |
2014-09-18 |
Dana-Farber Cancer Institute, Inc. |
Flavivirus neutralizing antibodies and methods of use thereof
|
ES2798307T3
(en)
|
2013-03-15 |
2020-12-10 |
Hoffmann La Roche |
Antioxidant Cell Culture Compositions and Procedures for Polypeptide Production
|
JP6482525B2
(en)
|
2013-03-15 |
2019-03-13 |
メモリアル スローン ケタリング キャンサー センター |
High affinity anti-GD2 antibody
|
EA201890895A1
(en)
|
2013-03-15 |
2019-02-28 |
Зинджения, Инк. |
MULTIVALENT AND MONOVALENT MULTIS-SPECIFIC COMPLEXES AND THEIR APPLICATION
|
US9447193B2
(en)
|
2013-03-24 |
2016-09-20 |
Development Center For Biotechnology |
Methods for suppressing cancer by inhibition of TMCC3
|
BR112015024856A2
(en)
|
2013-03-27 |
2018-04-17 |
Genentech Inc |
determination or monitoring methods
|
EP2986717A1
(en)
|
2013-04-19 |
2016-02-24 |
The Regents of The University of California |
Lone star virus
|
RU2015147721A
(en)
|
2013-05-07 |
2017-06-15 |
Ринат Нейросаенз Корпорэйшн |
ANTIBODIES AGAINST GLUCAGON RECEPTOR AND METHODS OF USING THEM
|
MX368107B
(en)
|
2013-07-12 |
2019-09-18 |
Genentech Inc |
Elucidation of ion exchange chromatography input optimization.
|
BR112016000853A2
(en)
|
2013-07-16 |
2017-12-12 |
Genentech Inc |
methods for treating or delaying, reducing or inhibiting cancer relapse or progression and the progression of an immune-related disease in an individual, to increase, improve or stimulate an immune response or function in an individual and kit.
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
EP3022221B1
(en)
|
2013-07-18 |
2021-09-15 |
Taurus Biosciences, LLC |
Humanized antibodies with ultralong complementarity determining regions
|
BR112016002845A2
(en)
|
2013-08-12 |
2017-09-12 |
Genentech Inc |
compositions and methods for treating complement-associated conditions
|
EP3705494A3
(en)
|
2013-08-14 |
2020-12-09 |
Sachdev Sidhu |
Antibodies against frizzled proteins and methods of use thereof
|
WO2015031541A1
(en)
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Novel sez6 modulators and methods of use
|
EP3892294A1
(en)
|
2013-08-28 |
2021-10-13 |
AbbVie Stemcentrx LLC |
Site-specific antibody conjugation methods and compositions
|
MX2016002643A
(en)
|
2013-08-29 |
2016-10-04 |
|
Cell penetrating conjugates and methods of use thereof.
|
AU2014324703C1
(en)
|
2013-09-27 |
2020-10-29 |
Genentech, Inc. |
Anti-PDL1 antibody formulations
|
EA036577B1
(en)
|
2013-11-04 |
2020-11-25 |
Икнос Сайенсиз Са |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
SG10201810298VA
(en)
|
2013-11-13 |
2018-12-28 |
Pfizer |
Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
|
NZ759287A
(en)
|
2013-12-02 |
2022-10-28 |
Baylor College Medicine |
Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
AU2014364601A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies
|
US20150190506A1
(en)
|
2013-12-17 |
2015-07-09 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
MX2016007885A
(en)
|
2013-12-17 |
2017-01-11 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody.
|
KR102344991B1
(en)
|
2013-12-24 |
2021-12-28 |
잔센파마슈티카엔.브이. |
Anti-vista antibodies and fragments
|
US9982041B2
(en)
|
2014-01-16 |
2018-05-29 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
US20170044232A1
(en)
|
2014-02-04 |
2017-02-16 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2015143194A2
(en)
|
2014-03-19 |
2015-09-24 |
Dana-Farber Cancer Institute, Inc. |
Immunogenetic restriction on elicitation of antibodies
|
EP4324481A2
(en)
|
2014-03-21 |
2024-02-21 |
Teva Pharmaceuticals International GmbH |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
RU2016136716A
(en)
|
2014-03-27 |
2018-04-28 |
Дженентек, Инк. |
METHODS FOR DIAGNOSTIC AND TREATMENT OF INFLAMMATORY DISEASES OF THE GUT
|
WO2015161267A2
(en)
|
2014-04-18 |
2015-10-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanized and chimeric monoclonal antibodies to cd99
|
CN106714830B
(en)
|
2014-05-30 |
2020-08-25 |
上海复宏汉霖生物技术股份有限公司 |
anti-Epidermal Growth Factor Receptor (EGFR) antibodies
|
WO2015195835A2
(en)
|
2014-06-17 |
2015-12-23 |
The Regents Of The University Of California |
Improved alpha-v beta-8 antibodies
|
TWI695011B
(en)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
Monoclonal antibodies against her2 epitope and methods of use thereof
|
BR112017006825A2
(en)
|
2014-10-03 |
2017-12-12 |
Dana Farber Cancer Inst Inc |
antibodies to glucocorticoid-induced tumor necrosis factor receptor (gitr) and their methods of use
|
CA2962949C
(en)
|
2014-10-06 |
2024-03-05 |
Dana-Farber Cancer Institute, Inc. |
Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
|
KR102544705B1
(en)
|
2014-11-05 |
2023-06-15 |
제넨테크, 인크. |
Methods of producing two chain proteins in bacteria
|
WO2016073791A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
CA2967368A1
(en)
|
2014-11-17 |
2016-05-26 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
TWI595006B
(en)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
Anti-pd-1 antibodies and methods of use thereof
|
ES2789351T3
(en)
|
2015-01-13 |
2020-10-26 |
Hope City |
Peptide binding masks of CTLA4-binding proteins
|
EP3244910B1
(en)
|
2015-01-16 |
2020-09-16 |
City of Hope |
Cell penetrating antibodies
|
CN107430127B
(en)
|
2015-01-24 |
2020-08-28 |
中央研究院 |
Cancer markers and methods of use thereof
|
CA2975875A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
JP2018507868A
(en)
|
2015-02-26 |
2018-03-22 |
ジェネンテック, インコーポレイテッド |
Integrin beta 7 antagonist and method of treating Crohn's disease
|
RU2754041C2
(en)
|
2015-04-03 |
2021-08-25 |
Еурека Терапьютикс, Инк. |
Structures aimed at afp/mhc peptide complexes and types of their use
|
WO2016164835A1
(en)
|
2015-04-08 |
2016-10-13 |
Dana-Farber Cancer Institute, Inc. |
Humanized influenza monoclonal antibodies and methods of use thereof
|
CN108136002B
(en)
|
2015-04-13 |
2022-05-31 |
辉瑞公司 |
Therapeutic antibodies and their use
|
US10556956B2
(en)
|
2015-05-01 |
2020-02-11 |
Dana-Farber Cancer Institute, Inc. |
Pharmaceutical compositions comprising humanized anti-CCR4 IgG4 antibody
|
CA2986030A1
(en)
|
2015-05-15 |
2016-11-24 |
City Of Hope |
Chimeric antigen receptor compositions
|
EP3447075B1
(en)
|
2015-05-15 |
2023-08-09 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
AR105618A1
(en)
|
2015-05-29 |
2017-10-25 |
Genentech Inc |
METHODATION OF THE PROMOTER OF THE BINDING TO THE PROGRAMMED DEATH RECEIVER (PD-L1) IN CANCER
|
JP2018516933A
(en)
|
2015-06-02 |
2018-06-28 |
ジェネンテック, インコーポレイテッド |
Compositions and methods for treating neurological disorders using anti-IL-34 antibodies
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
CA2990360C
(en)
|
2015-06-24 |
2024-02-13 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
CA3025896A1
(en)
|
2015-07-23 |
2017-01-26 |
The Regents Of The University Of California |
Antibodies to coagulation factor xia and uses thereof
|
CN114306627A
(en)
|
2015-08-06 |
2022-04-12 |
希望之城 |
Cell penetrating protein-antibody conjugates and methods of use thereof
|
EP3344657A1
(en)
|
2015-09-02 |
2018-07-11 |
The Regents of the University of Colorado, A Body Corporate |
Compositions and methods for modulating t-cell mediated immune response
|
JP2018529747A
(en)
|
2015-10-06 |
2018-10-11 |
ジェネンテック, インコーポレイテッド |
Methods for treating multiple sclerosis
|
JP7030689B2
(en)
|
2015-10-23 |
2022-03-07 |
ファイザー インコーポレイティッド |
Anti-IL-2 antibody and its composition and use
|
EP3386549A4
(en)
|
2015-12-10 |
2019-08-07 |
City of Hope |
Cell penetrating cyanine-coupled antibodies
|
AU2016379425B2
(en)
|
2015-12-24 |
2021-11-11 |
Corvus Pharmaceuticals, Inc. |
Methods of treating cancer
|
JP7046814B2
(en)
|
2015-12-30 |
2022-04-04 |
ジェネンテック, インコーポレイテッド |
Use of tryptophan derivatives for protein formulations
|
JP7008023B2
(en)
|
2015-12-30 |
2022-01-25 |
ジェネンテック, インコーポレイテッド |
Formulation with reduced polysorbate degradation
|
CN108368179B
(en)
|
2016-01-08 |
2022-08-23 |
豪夫迈·罗氏有限公司 |
Methods of treating CEA positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD 3 bispecific antibodies
|
DK3405490T3
(en)
|
2016-01-21 |
2022-01-10 |
Pfizer |
MONO- AND BISPECIFIC ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III AND CD3 AND USES THEREOF
|
WO2017132279A1
(en)
|
2016-01-25 |
2017-08-03 |
Genentech, Inc. |
Methods for assaying t-cell dependent bispecific antibodies
|
JP2019509721A
(en)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
Mutant smoothened and method of using the same
|
TWI756204B
(en)
|
2016-02-12 |
2022-03-01 |
比利時商楊森製藥公司 |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
CA3019164A1
(en)
|
2016-03-29 |
2017-10-05 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
|
CA3019130A1
(en)
|
2016-04-01 |
2017-10-05 |
The Regents Of The University Of California |
Inhibitors of integrin alpha 5 beta 1 and methods of use
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
KR20230124093A
(en)
|
2016-05-10 |
2023-08-24 |
제넨테크, 인크. |
Methods of decreasing trisulfide bonds during recombinant production of polypeptides
|
WO2017218977A2
(en)
|
2016-06-17 |
2017-12-21 |
Genentech, Inc. |
Purification of multispecific antibodies
|
JP7082967B2
(en)
|
2016-07-22 |
2022-06-09 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody and its usage
|
CN106079858B
(en)
*
|
2016-08-03 |
2017-05-17 |
钟晴晴 |
Silk screen printer
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
JP7250674B2
(en)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
CANCER TREATMENT AND DIAGNOSTIC METHOD
|
CN115598231A
(en)
|
2016-08-15 |
2023-01-13 |
豪夫迈·罗氏有限公司(Ch) |
Chromatographic method for quantifying nonionic surfactant in composition containing nonionic surfactant and polypeptide
|
WO2018045379A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
BR112019004214A2
(en)
|
2016-09-06 |
2019-05-28 |
Dana Farber Cancer Inst Inc |
Methods to Treat or Prevent Zika Virus Infection
|
TW201825674A
(en)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
Oncolytic virus expressing bispecific engager molecules
|
WO2018055574A1
(en)
|
2016-09-23 |
2018-03-29 |
Teva Pharmaceuticals International Gmbh |
Treating refractory migraine
|
AU2017331592A1
(en)
|
2016-09-23 |
2019-04-11 |
Teva Pharmaceuticals International Gmbh |
Treating cluster headache
|
US10954304B2
(en)
|
2016-09-29 |
2021-03-23 |
The Regents Of The University Of California |
Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy
|
MX2019003703A
(en)
|
2016-09-30 |
2020-08-13 |
Janssen Biotech Inc |
Safe and effective method of treating psoriasis with anti-il23 specific antibody.
|
JP2020503256A
(en)
|
2016-11-04 |
2020-01-30 |
ノビミューン エスアー |
Anti-CD19 antibodies and methods of using them
|
US11008325B2
(en)
|
2016-11-14 |
2021-05-18 |
Virginia Commonwealth University |
Inhibitors of cancer invasion, attachment, and/or metastasis
|
AU2017362222A1
(en)
|
2016-11-16 |
2019-05-30 |
Janssen Biotech, Inc. |
Method of treating psoriasis with anti-IL-23 specific antibody
|
TW201825515A
(en)
|
2017-01-04 |
2018-07-16 |
美商伊繆諾金公司 |
Met antibodies and immunoconjugates and uses thereof
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
US11198735B2
(en)
|
2017-03-03 |
2021-12-14 |
Rinat Neuroscience Corp. |
Anti-GITR antibodies and methods of use thereof
|
CA3059542A1
(en)
|
2017-04-12 |
2018-10-18 |
Pfizer Inc. |
Antibodies having conditional affinity and methods of use thereof
|
RU2665790C1
(en)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Monoclonal pd-l1 antibody
|
US11236151B2
(en)
|
2017-04-25 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
|
JOP20190256A1
(en)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
Newcastle disease viruses and uses thereof
|
CA3065008A1
(en)
|
2017-05-26 |
2018-11-29 |
Novimmune Sa |
Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
|
RU2758513C2
(en)
|
2017-06-02 |
2021-10-29 |
Пфайзер Инк. |
Antibodies specific to flt3 and their applications
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
Chimeric antigen receptors and bispecific antibodies for treatment of mantle cell lymphoma
|
RU2698048C2
(en)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
Monoclonal antibody to il-5rα
|
EP3746482A1
(en)
|
2018-02-01 |
2020-12-09 |
Pfizer Inc |
Antibodies specific for cd70 and their uses
|
CA3092551A1
(en)
|
2018-03-05 |
2019-09-12 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
AU2019235523A1
(en)
|
2018-03-14 |
2020-10-29 |
Novimmune Sa |
Anti-CD3 epsilon antibodies and methods of use thereof
|
CN108357203A
(en)
*
|
2018-04-23 |
2018-08-03 |
广州市威顿彩印有限公司 |
A kind of color printing producing line rotary blade type drying equipment and its application method
|
EP3788071A1
(en)
|
2018-05-02 |
2021-03-10 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
MA52590A
(en)
|
2018-05-11 |
2021-03-17 |
Janssen Biotech Inc |
METHODS OF TREATING DEPRESSION USING IL-23 ANTIBODIES
|
MX2020012607A
(en)
|
2018-05-23 |
2021-01-29 |
Pfizer |
Antibodies specific for gucy2c and uses thereof.
|
WO2019224385A2
(en)
|
2018-05-24 |
2019-11-28 |
Glenmark Pharmaceuticals S.A. |
Combined bispecific antibody and immuno-oncology therapies
|
EP3810777A4
(en)
|
2018-06-21 |
2022-03-30 |
Yumanity Therapeutics, Inc. |
Compositions and methods for the treatment and prevention of neurological disorders
|
MX2020014091A
(en)
|
2018-06-23 |
2021-05-27 |
Genentech Inc |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor.
|
EP3813951A1
(en)
|
2018-06-29 |
2021-05-05 |
City of Hope |
Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
BR112021000673A2
(en)
|
2018-07-18 |
2021-04-20 |
Genentech, Inc. |
methods for treating an individual with lung cancer, kits, anti-pd-l1 antibody and compositions
|
EP3824295A4
(en)
|
2018-07-18 |
2022-04-27 |
Janssen Biotech, Inc. |
Sustained response predictors after treatment with anti-il23 specific antibody
|
KR20210042936A
(en)
|
2018-08-08 |
2021-04-20 |
제넨테크, 인크. |
Use of tryptophan derivatives and L-methionine for protein preparation
|
US20210221864A1
(en)
|
2018-08-24 |
2021-07-22 |
City Of Hope |
Masked cytokine conjugates
|
WO2020061381A1
(en)
|
2018-09-19 |
2020-03-26 |
La Jolla Institute For Immunology |
Ptprs and proteoglycans in rheumatoid arthritis
|
MX2021003213A
(en)
|
2018-09-21 |
2021-05-12 |
Genentech Inc |
Diagnostic methods for triple-negative breast cancer.
|
SG11202104104VA
(en)
|
2018-11-05 |
2021-05-28 |
Genentech Inc |
Methods of producing two chain proteins in prokaryotic host cells
|
WO2020104943A2
(en)
|
2018-11-20 |
2020-05-28 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-il-23 specific antibody
|
WO2020213724A1
(en)
|
2019-04-19 |
2020-10-22 |
中外製薬株式会社 |
Chimeric receptor recognizing modification site of antibody
|
CA3138241A1
(en)
|
2019-05-23 |
2020-11-26 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
CA3142580A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
AR119264A1
(en)
|
2019-06-05 |
2021-12-09 |
Genentech Inc |
METHOD FOR REUSE OF CHROMATOGRAPHY
|
EP3998083A4
(en)
|
2019-07-12 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
JP2022541652A
(en)
|
2019-07-26 |
2022-09-26 |
ヴァンダービルト ユニバーシティ |
Human monoclonal antibody against enterovirus D68
|
TW202120551A
(en)
|
2019-08-12 |
2021-06-01 |
美商普瑞諾生物科技公司 |
Methods and compositions for promoting and potentiating t‐cell mediated immune responses through adcc targeting of cd39 expressing cells
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
WO2021138454A1
(en)
|
2019-12-30 |
2021-07-08 |
City Of Hope |
Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
|
WO2021163265A1
(en)
|
2020-02-11 |
2021-08-19 |
Vanderbilt University |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
|
UY39135A
(en)
|
2020-03-26 |
2021-10-29 |
Univ Vanderbilt |
HUMAN MONOCLONAL ANTIBODIES TARGETED AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
SG11202112792WA
(en)
|
2020-04-28 |
2021-12-30 |
Univ Rockefeller |
Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
|
IL299039A
(en)
|
2020-06-16 |
2023-02-01 |
Genentech Inc |
Methods and compositions for treating triple-negative breast cancer
|
CN116323668A
(en)
|
2020-07-17 |
2023-06-23 |
辉瑞公司 |
Therapeutic antibodies and uses thereof
|
US11919945B2
(en)
|
2020-11-04 |
2024-03-05 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies
|
WO2022155324A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
AU2022210221A1
(en)
|
2021-01-20 |
2023-08-31 |
Oncoresponse, Inc. |
Immunomodulatory antibodies and uses thereof
|
AU2022233792A1
(en)
|
2021-03-12 |
2023-10-26 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
KR20230156764A
(en)
|
2021-03-12 |
2023-11-14 |
얀센 바이오테크 인코포레이티드 |
Method for treating psoriatic arthritis patients with inadequate response to TNF therapy by anti-IL23 specific antibody
|
WO2022200387A1
(en)
|
2021-03-22 |
2022-09-29 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
AU2022245196A1
(en)
|
2021-03-22 |
2023-09-21 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
WO2023073615A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
WO2023081471A1
(en)
|
2021-11-05 |
2023-05-11 |
Dana-Farber Cancer Institute, Inc. |
Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
|
US20230151087A1
(en)
|
2021-11-15 |
2023-05-18 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
US20230159633A1
(en)
|
2021-11-23 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
CN114485122A
(en)
*
|
2022-02-24 |
2022-05-13 |
广西青松木业有限公司 |
Tunnel type timber veneer drying production line
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
US20230312703A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis with IL-23 Specific Antibody
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
US20230364020A1
(en)
|
2022-04-01 |
2023-11-16 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
US20230374122A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
|